U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C2H4NO2.Cu.H2O
Molecular Weight 229.679
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CUPRIC GLYCINATE MONOHYDRATE

SMILES

O.[Cu++].NCC([O-])=O.NCC([O-])=O

InChI

InChIKey=IBCBKVAHJPKRLA-UHFFFAOYSA-L
InChI=1S/2C2H5NO2.Cu.H2O/c2*3-1-2(4)5;;/h2*1,3H2,(H,4,5);;1H2/q;;+2;/p-2

HIDE SMILES / InChI

Molecular Formula Cu
Molecular Weight 63.546
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C2H5NO2
Molecular Weight 75.0666
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper dihydroxide also known as Schweizer's Reagent dissolves cellulose; used in rayon production.

CNS Activity

Curator's Comment: Known to be CNS active in zebrafish. Human data not available.

Originator

Sources: http://pubs.acs.org/doi/abs/10.1021/ja01512a012Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
COPPER•MAX

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Preventing
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
The effectiveness of ecologically acceptable ways of protection of field-grown tomato (Lycopersicon lycopersicum (L.) Karsten) from tomato late blight (Phytophthora infestans (Mont.) de Bary) in extreme weather conditions.
2001
Anti-ovulatory activity of H2 receptor blockers in albino rabbits--a preliminary study.
2011 Apr
Molecular responses of human lung epithelial cells to the toxicity of copper oxide nanoparticles inferred from whole genome expression analysis.
2011 Dec 27
Probing the chemical nature of dihydrogen complexation to transition metals, a gas phase case study: H2-CuF.
2013 Jan 18
Activation of Erk and p53 regulates copper oxide nanoparticle-induced cytotoxicity in keratinocytes and fibroblasts.
2014
CuO nanoparticles induce apoptosis by impairing the antioxidant defense and detoxification systems in the mouse hippocampal HT22 cell line: protective effect of crocetin.
2015 Jun
Dissecting copper homeostasis in diabetes mellitus.
2017 Apr
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.
2017 Apr 1
Comparison of the efficacy of a commercial footbath product with copper sulfate for the control of digital dermatitis.
2017 Jul
Patents

Sample Use Guides

In Vivo Use Guide
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration: Intravenous
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:58:38 UTC 2023
Edited
by admin
on Fri Dec 15 15:58:38 UTC 2023
Record UNII
163J4O4DFH
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CUPRIC GLYCINATE MONOHYDRATE
Common Name English
COPPER, BIS(GLYCINATO-.KAPPA.N,.KAPPA.O)-, MONOHYDRATE
Common Name English
COPPER, BIS(GLYCINATO-N,O)-, MONOHYDRATE
Common Name English
COPPER, BIS(GLYCINATO)-, MONOHYDRATE
Common Name English
COPPER, BIS(GLYCINATO-.KAPPA.N,.KAPPA.O)-, HYDRATE (1:1)
Common Name English
CUPRIC GLYCINATE HYDRATE
Common Name English
Code System Code Type Description
FDA UNII
163J4O4DFH
Created by admin on Fri Dec 15 15:58:38 UTC 2023 , Edited by admin on Fri Dec 15 15:58:38 UTC 2023
PRIMARY
PUBCHEM
71587023
Created by admin on Fri Dec 15 15:58:38 UTC 2023 , Edited by admin on Fri Dec 15 15:58:38 UTC 2023
PRIMARY
EPA CompTox
DTXSID20171302
Created by admin on Fri Dec 15 15:58:38 UTC 2023 , Edited by admin on Fri Dec 15 15:58:38 UTC 2023
PRIMARY
CAS
18253-80-0
Created by admin on Fri Dec 15 15:58:38 UTC 2023 , Edited by admin on Fri Dec 15 15:58:38 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE